These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11427658)

  • 21. Chronic hepatitis C after high-dose intravenous immunoglobulin.
    Pawlotsky JM; Bouvier M; Deforges L; Duval J; Bierling P; Dhumeaux D
    Transfusion; 1994 Jan; 34(1):86-7. PubMed ID: 8273141
    [No Abstract]   [Full Text] [Related]  

  • 22. [Intravenously administered immunoglobulins as a first-choice method in juvenile dermatomyositis].
    Wokke JH
    Ned Tijdschr Geneeskd; 1993 Nov; 137(48):2509-10. PubMed ID: 8272132
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of iodinated contrast media in patients with chronic renal insufficiency and in end-stage renal disease.
    Nora NA; Krumlovsky FA
    Int J Artif Organs; 1991 Apr; 14(4):196-8. PubMed ID: 2060986
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous immunoglobulin for treatment of gastro-intestinal haemorrhage in dermatomyositis.
    Marie I; Levesque H; Cailleux N; Courtois H; Guédon C
    Ann Rheum Dis; 2001 Jul; 60(7):723-4. PubMed ID: 11436864
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravenous immunoglobulin and hepatitis C virus: the Boston episode.
    Schneider LC; Jonas MM; Baron MJ; Mast EF; Alter MJ; Schonberger LB; Lambert S; Coleman P; Bresee JS
    Clin Ther; 1996; 18 Suppl B():108-9. PubMed ID: 8930448
    [No Abstract]   [Full Text] [Related]  

  • 26. [Nephrotoxicity of contrast media in the diabetic (apropos of 5 cases)].
    Mahjoub S; Ben Dhia N; Bouhaouala H; Chaabane M; Elmay M; Gannouni A
    Tunis Med; 1986; 64(6-7):619-24. PubMed ID: 3787751
    [No Abstract]   [Full Text] [Related]  

  • 27. [Acute renal failure in patients with diabetes mellitus].
    Suzuki S; Tsuchida H; Mimura N
    Nihon Rinsho; 1991 Jun; 49(6):1281-5. PubMed ID: 1909384
    [No Abstract]   [Full Text] [Related]  

  • 28. [Human immunoglobulins, adverse drug reaction, prevention].
    Grenouillet-Delacrea M; Longy-Boursier M
    Rev Med Interne; 2008 Jun; 29 Spec No 2():24-8. PubMed ID: 18927984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.
    Luzi G; Diamanti AP; Germano V; Laganà B; Di Rosa R; Salemi S; Stoppacciaro A; D'Amelio R
    Clin Immunol; 2007 Nov; 125(2):127-30. PubMed ID: 17720626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute renal failure following intravenous pyelography.
    Chen WY; Yen TS; Cheng JT; Hsieh BS; Hsu FY
    Taiwan Yi Xue Hui Za Zhi; 1970 Apr; 69(4):229-33. PubMed ID: 5273435
    [No Abstract]   [Full Text] [Related]  

  • 33. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis.
    Marie I; Hachulla E; Levesque H; Reumont G; Ducrotte P; Cailleux N; Hatron PY; Devulder B; Courtois H
    J Rheumatol; 1999 Dec; 26(12):2706-9. PubMed ID: 10606390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of early treatment with intravenous immunoglobulins in severe forms of dermatomyositis].
    Escriche D; de la Cruz J; Moreno MJ; Romero J
    Med Clin (Barc); 1995 Jan; 104(2):79. PubMed ID: 7869785
    [No Abstract]   [Full Text] [Related]  

  • 35. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy.
    Mosca M; Strigini F; Carmignani A; D'ascanio A; Genazzani AR; Bombardieri S
    Arthritis Rheum; 2005 Feb; 53(1):119-21. PubMed ID: 15696574
    [No Abstract]   [Full Text] [Related]  

  • 36. Computerized tomography--how safe?
    Diaz-Buxo JA; Farmer CD; Chandler JT; Walker PJ
    Arch Intern Med; 1980 Sep; 140(9):1253. PubMed ID: 7406629
    [No Abstract]   [Full Text] [Related]  

  • 37. Respiratory muscle weakness with dermatomyositis during pregnancy: successful treatment with intravenous immunoglobulin therapy.
    Nozaki Y; Ikoma S; Funauchi M; Kinoshita K
    J Rheumatol; 2008 Nov; 35(11):2289. PubMed ID: 19004066
    [No Abstract]   [Full Text] [Related]  

  • 38. [Renal complications from intravenous immunoglobulins. Role of renal hemodynamic factors].
    Poullin P; Moulin B; Ollier J; Benaicha M; Olmer M; Gabriel B
    Presse Med; 1995 Mar; 24(9):441-4. PubMed ID: 7746817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of intravenous immunoglobulin with regard to hepatitis C virus.
    Yu MW; Mason BL; Guo ZP; Tankersley DL
    Clin Ther; 1996; 18 Suppl B():71-2. PubMed ID: 8930443
    [No Abstract]   [Full Text] [Related]  

  • 40. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.